Show simple item record

dc.contributor.authorJoffe, J. K.
dc.contributor.authorCafferty, F. H.
dc.contributor.authorMurphy, L.
dc.contributor.authorRustin, G. J. S.
dc.contributor.authorSohaib, S. A.
dc.contributor.authorSwift, S.
dc.contributor.authorNoor, D.
dc.contributor.authorWade, S.
dc.contributor.authorJames, E.
dc.contributor.authorGabe, R.
dc.contributor.authorStenning, S. P.
dc.contributor.authorHall, M.
dc.contributor.authorSharma, A.
dc.contributor.authorBraybrooke, J.
dc.contributor.authorShamash, J.
dc.contributor.authorLogue, John P
dc.contributor.authorTaylor, H. H.
dc.contributor.authorKaplan, R. S.
dc.contributor.authorHuddart, R. A.
dc.contributor.authorGrp, T. T. M.
dc.date.accessioned2021-05-18T08:48:06Z
dc.date.available2021-05-18T08:48:06Z
dc.date.issued2021en
dc.identifier.citationJoffe JK, Cafferty FH, Murphy L, Rustin GJS, Sohaib SA, Swift S, et al. Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST). JCO. 2021 Feb 20;39(6_suppl):374–374.en
dc.identifier.doi10.1200/JCO.2021.39.6_suppl.374en
dc.identifier.urihttp://hdl.handle.net/10541/624008
dc.description.abstractBackground: Survival after orchiectomy in stage I seminoma is almost 100%. CT surveillance is an international standard of care, and avoids adjuvant therapy. In this young population, who are unlikely to die from testicular cancer, minimizing irradiation is vital. The Trial of Imaging and Surveillance in Seminoma Testis (TRISST, NCT00589537), assessed whether CTs can safely be reduced, or replaced with MRI, without an unacceptable increase in advanced relapses. Methods: TRISST is a phase III, multicenter, non-inferiority, factorial trial. Eligible men had undergone orchiectomy for stage I seminoma with no adjuvant therapy planned. Randomization was to: 7 CTs (6, 12, 18, 24, 36, 48, 60 months (m) after randomization); 7 MRIs (same schedule); 3 CTs (6, 18, 36m); or 3 MRIs (same schedule). Follow-up was for 6 years. The primary outcome is 6-year incidence of RMH stage ≥IIC relapse, aiming to exclude an increase ≥5.7% (from 5.7% to 11.4%) with MRI (vs CT) or 3 scans (vs 7); target n=660, all contributing to both comparisons. Secondary outcomes include relapse ≥3cm, disease-free and overall survival (DFS, OS). Results: 669 men enrolled from 35 UK centers (2008-2014); mean tumor size 2.9cm, 358 (54%) were low risk (≤4cm, no rete testis invasion). Median follow-up was 72m. 82 (12%) patients relapsed. Incidence of stage ≥IIC relapse was low in all groups (n=10). More events occurred with 3 scans vs 7, though non-inferior based on design criteria: 9 (2.8%) vs 1 (0.3%), 2.5% increase, 90% CI 1.0% to 4.1% (intent-to-treat, ITT). 4/9 in 3-scan arms could potentially have been detected earlier with the 7-scan schedule. Fewer events occurred with MRI vs CT: 2 (0.6%) vs 8 (2.5%), 1.9% decrease, 90% CI -3.5% to -0.3% (ITT). Per protocol results were similar. Incidence of relapse ≥3cm was 3.7%; non-inferiority was shown for both comparisons. In all groups, most relapses were detected at scheduled imaging; very few occurred beyond 3 years (5 in 558 at risk, <1%). Relapse treatment outcomes were good (81% complete response) with no tumor-related deaths. 5-year DFS and OS were 87% and 99%, similar across groups. Conclusions:Surveillance is a safe management approach in stage I seminoma – advanced relapse is rare, salvage treatment successful, and long-term outcomes excellent, regardless of imaging frequency or modality. Relapse beyond 3 years is rare and imaging may be unnecessary. MRI is non-inferior to CT, avoids irradiation and should be recommended.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2021.39.6_suppl.374en
dc.titleImaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentHuddersfield Royal Infirmary, West Yorkshireen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen


This item appears in the following Collection(s)

Show simple item record